Mindstate Design Labs Analysis: $12M Raised
What is Mindstate Design Labs?
Mindstate Design Labs develops a neurotech AI platform for psychedelic drug development, focusing on precision design of altered states of consciousness.
Product Features & Capabilities
- Neurotech AI platform, target discovery platform (Osmanthus), phenotypic screening, precision design of modified conscious states, psychedelic primer and probe compounds, therapeutic utility candidates.
How much Mindstate Design Labs raised
1 - $11.5 million
36 months ago (February 2022)Lead Investor: Not specified in the sources.
Who are the founders of Mindstate Design Labs
DD
Dillan DiNardo
Co-Founder & CEO
TR
Thomas Ray, PhD
Scientific Co-Founder
PW
Paul Wren, PhD
Chief Scientific Officer
Market Focus
Mindstate Design Labs primarily focuses on the neurotechnology and psychedelic drug development industry, specifically in mapping the biological basis of altered states of consciousness to enable precision design of modified conscious states.
Competitors Overview
Mindstate Design Labs operates in the neurotech and psychedelic drug development market, where it faces competition from several notable companies:
- Atai Life Sciences NV: This company focuses on developing psychedelic compounds for mental health treatments. Atai has a diverse portfolio of pr
Business Model
AI-driven drug development and clinical trials funded by investments and partnerships.
Investors
- Initialized Capital
- Metaplanet Holdings
- Negev Capital
- Day One Ventures
- K50 Ventures
- Page One Ventures
- Max Hodak (Neuralink cofounder)
- Naval Ravikant (former AngelList CEO)
- Fred Ehrsam (Paradigm cofounder)
- Apoorva Mehta (Instacart founder)
- Garry Tan (Initialized Capital)
- Angel
See something that needs updating? Suggest edits to this profile.